https://www.selleckchem.com/pr....oducts/Gefitinib.htm
In the OS cohort, 8/16 patients had osseous metastases; 100% of these patients were detected on FDG PET/CT and 75% on BS. Thirty-one bony lesions were seen on imaging in OS patients; 100% of these were identified on FDG PET/CT but only 29% on BS. In the EWS cohort, 6/15 patients had osseous metastases; 100% of these patients were detected on FDG PET/CT and 50% on BS. Eighteen bony lesions were seen on imaging in EWS patients; 94% of these were identified on FDG PET/CT, but only 28% on BS. For patients in our institution with OS or EWS
Like
Comment
Share
